Rate Of ReturnNovo Nordisk remains a world-class company with leading diabetes and obesity treatments, but I'm re-evaluating my investment. Competition in the obesity market is intensifying, and future growth may become less predictable. I may eventually switch to a healthcare company with a more diversified business and lower execution risk while continuing to monitor Novo Nordisk's progress.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
